Jade Biosciences, Inc. Research and Development Expense
Jade Biosciences, Inc. (JBIO) reported Research and Development Expense of $50.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Jade Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $50.06M, a 122.05% increase year-over-year.
- Jade Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $36.05M, a 80.06% increase year-over-year.
- Jade Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $28.54M, a 62.40% increase year-over-year.
- Jade Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $22.01M, a 62.06% increase year-over-year.
- Jade Biosciences, Inc. research and development expense for fiscal 2025 was $93.12M, a 75.08% increase from fiscal 2024.
- Jade Biosciences, Inc. research and development expense for fiscal 2024 was $53.19M, a 17.18% decline from fiscal 2023.
- Jade Biosciences, Inc. research and development expense for fiscal 2023 was $64.22M, a 66.28% increase from fiscal 2022.
- Jade Biosciences, Inc. research and development expense for fiscal 2022 was $38.62M, a 157.70% increase from fiscal 2021.
| Period end | Research and Development Expense 0 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $50.06M 10-Q · filed 2026-08-10 | $86.12M 10-Q · filed 2026-08-10 | $114.66M derived: sum of 3 quarters · filed 2026-08-10 | $136.67M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $36.05M 10-Q · filed 2026-05-07 | $64.59M derived: sum of 2 quarters · filed 2026-05-07 | $86.60M derived: sum of 3 quarters · filed 2026-05-07 | $109.15M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $28.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $50.55M derived: sum of 2 quarters · filed 2026-03-06 | $73.10M derived: sum of 3 quarters · filed 2026-08-10 | $93.12M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | $22.01M 10-Q · filed 2025-11-14 | $44.56M derived: sum of 2 quarters · filed 2026-08-10 | $64.58M 10-Q · filed 2025-11-14 | $82.16M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $22.55M 10-Q · filed 2026-08-10 | $42.57M 10-Q · filed 2026-08-10 | $60.15M derived: sum of 3 quarters · filed 2026-08-10 | $73.80M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $20.02M 10-Q · filed 2026-05-07 | $37.60M derived: sum of 2 quarters · filed 2026-05-07 | $51.26M derived: sum of 3 quarters · filed 2026-05-07 | $72.50M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $17.57M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $31.23M 10-K · filed 2026-03-06 | $52.48M derived: sum of 3 quarters · filed 2026-03-06 | $53.19M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $13.58M 10-Q · filed 2025-11-14 | $10.33M 10-Q · filed 2024-11-12 | $34.91M derived: sum of 2 quarters · filed 2025-11-14 | $51.66M 10-Q · filed 2024-11-12 | $72.80M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $78.00K 10-Q · filed 2025-08-13 | $21.25M 10-Q · filed 2024-08-12 | $41.33M 10-Q · filed 2024-08-12 | $59.14M derived: sum of 3 quarters · filed 2025-04-25 | $76.03M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | $20.08M 10-Q · filed 2025-04-25 | $37.89M derived: sum of 2 quarters · filed 2025-04-25 | $54.78M derived: sum of 3 quarters · filed 2025-04-25 | $70.81M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | $17.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $34.70M derived: sum of 2 quarters · filed 2025-03-27 | $50.73M derived: sum of 3 quarters · filed 2025-03-27 | $64.22M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $16.88M 10-Q · filed 2024-11-12 | $32.92M derived: sum of 2 quarters · filed 2024-11-12 | $46.41M 10-Q · filed 2024-11-12 | $58.63M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $16.03M 10-Q · filed 2024-08-12 | $29.52M 10-Q · filed 2024-08-12 | $41.74M derived: sum of 3 quarters · filed 2024-08-12 | $52.53M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $13.49M 10-Q · filed 2024-05-13 | $25.71M derived: sum of 2 quarters · filed 2024-05-13 | $36.49M derived: sum of 3 quarters · filed 2024-05-13 | $44.85M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $12.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $23.00M derived: sum of 2 quarters · filed 2024-03-25 | $31.37M derived: sum of 3 quarters · filed 2024-03-25 | $38.62M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $10.78M 10-Q · filed 2023-11-13 | $19.15M derived: sum of 2 quarters · filed 2023-11-13 | $26.40M 10-Q · filed 2023-11-13 | $31.45M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $8.36M 10-Q · filed 2023-08-14 | $15.62M 10-Q · filed 2023-08-14 | $20.66M derived: sum of 3 quarters · filed 2023-08-14 | $24.08M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $7.25M 10-Q · filed 2023-05-15 | $12.30M derived: sum of 2 quarters · filed 2023-05-15 | $15.72M derived: sum of 3 quarters · filed 2023-05-15 | $20.05M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $8.46M derived: sum of 2 quarters · filed 2023-03-29 | $12.79M derived: sum of 3 quarters · filed 2023-03-29 | $14.99M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $3.42M 10-Q · filed 2022-11-14 | $7.75M derived: sum of 2 quarters · filed 2022-11-14 | $9.94M 10-Q · filed 2022-11-14 | $13.24M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $4.33M 10-Q · filed 2022-08-15 | $6.52M 10-Q · filed 2022-08-15 | $9.82M derived: sum of 3 quarters · filed 2022-08-15 | $11.79M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $2.20M 10-Q · filed 2022-05-16 | $5.49M derived: sum of 2 quarters · filed 2022-05-16 | $7.46M derived: sum of 3 quarters · filed 2022-05-16 | $8.93M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $5.26M derived: sum of 2 quarters · filed 2022-03-30 | $6.73M derived: sum of 3 quarters · filed 2022-03-30 | $7.94M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $1.97M 10-Q · filed 2021-11-15 | $3.44M derived: sum of 2 quarters · filed 2021-11-15 | $4.64M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.47M 10-Q · filed 2021-08-16 | $2.68M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |